We wish to share with you the latest in oncology. This time it is immunotherapy yet again. In this new study published in Lancet Oncology – Nivolumab succeeded in metastatic Anal canal cancers. It produced responses in excess of 25% with few complete responses and most of these responses where ever lasting at least at the time of data cut-off.
Interestingly, anal canal cancers are result of HPV infection more often than not and where E6 and E7 protein is
upregulated (HPV derived proteins) – immunotherapy seems to work even better as these proteins attract tumor immune response and hence make immunotherapy work better. Now we have another agent in our armamentarium to treat anal cancers where no head way has been made since last decade.
Please find the full text article attached for your reference.